Annual Financials for HilleVax Inc.
Fiscal year is January-December. All values USD millions. |
| | 2019 | 2020 | 2021 |
5-year trend |
Sales/Revenue
|
- | - | - | - | - | |
Sales Growth |
- | - | - | - | - | |
Cost of Goods Sold (COGS) incl. D&A |
- | - | - | - | 3,000 | |
COGS excluding D&A |
- | - | - | - | - | |
Depreciation & Amortization Expense |
- | - | - | - | 3,000 | |
Depreciation |
- | - | - | - | 3,000 | |
Amortization of Intangibles |
- | - | - | - | - | |
COGS Growth |
- | - | - | - | - | |
Gross Income |
- | - | - | - | (3,000) | |
Gross Income Growth |
- | - | - | - | - | |
Gross Profit Margin |
- | - | - | - | - | NA |
|
| | 2019 | 2020 | 2021 |
5-year trend |
SG&A Expense |
- | - | 633,000 | 1.3M | 15.77M | |
Research & Development |
- | - | - | - | 10.01M | |
Other SG&A |
- | - | - | - | - | |
SGA Growth |
- | - | - | 104.58% | 1,117.53% | |
Other Operating Expense |
- | - | - | - | - | |
Unusual Expense |
- | - | 31,000 | 779,000 | 83.77M | |
EBIT after Unusual Expense |
- | - | (664,000) | (2.07M) | (99.54M) | |
Non Operating Income/Expense |
- | - | - | - | (23,000) | |
Non-Operating Interest Income |
- | - | - | - | - | |
Equity in Affiliates (Pretax) |
- | - | - | - | - | |
Interest Expense |
- | - | 9,000 | 29,000 | 2.84M | |
Interest Expense Growth |
- | - | - | 222.22% | 9,706.90% | |
Gross Interest Expense |
- | - | 9,000 | 29,000 | 2.84M | |
Interest Capitalized |
- | - | - | - | - | |
Pretax Income |
- | - | (673,000) | (2.1M) | (102.41M) | |
Pretax Income Growth |
- | - | - | -212.48% | -4,769.61% | |
Pretax Margin |
- | - | - | - | - | NA |
Income Tax |
- | - | - | - | - | |
Income Tax - Current Domestic |
- | - | - | - | - | |
Income Tax - Current Foreign |
- | - | - | - | - | |
Income Tax - Deferred Domestic |
- | - | - | - | - | |
Income Tax - Deferred Foreign |
- | - | - | - | - | |
Income Tax Credits |
- | - | - | - | - | |
Equity in Affiliates |
- | - | - | - | - | |
Other After Tax Income (Expense) |
- | - | - | - | - | |
Consolidated Net Income |
- | - | (673,000) | (2.1M) | (102.41M) | |
Minority Interest Expense |
- | - | - | - | - | |
Net Income |
- | - | (673,000) | (2.1M) | (102.41M) | |
Net Income Growth |
- | - | - | -212.48% | -4,769.61% | |
Net Margin Growth |
- | - | - | - | - | NA |
Extraordinaries & Discontinued Operations |
- | - | - | - | - | |
Extra Items & Gain/Loss Sale Of Assets |
- | - | - | - | - | |
Cumulative Effect - Accounting Chg |
- | - | - | - | - | |
Discontinued Operations |
- | - | - | - | - | |
Net Income After Extraordinaries |
- | - | (673,000) | (2.1M) | (102.41M) | |
Preferred Dividends |
- | - | - | - | - | |
Net Income Available to Common |
- | - | (673,000) | (2.1M) | (102.41M) | |
EPS (Basic) |
- | - | (0.02) | (0.07) | (3.39) | |
EPS (Basic) Growth |
- | - | - | -212.56% | -4,766.57% | |
Basic Shares Outstanding |
- | - | 30.19M | 30.19M | 30.19M | |
EPS (Diluted) |
- | - | (0.02) | (0.07) | (3.39) | |
EPS (Diluted) Growth |
- | - | - | -212.56% | -4,766.57% | |
Diluted Shares Outstanding |
- | - | 30.19M | 30.19M | 30.19M | |
EBITDA |
- | - | (633,000) | (1.3M) | (15.77M) | |
EBITDA Growth |
- | - | - | -104.58% | -1,117.53% | |
EBITDA Margin |
- | - | - | - | - | NA |